These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 20626711

  • 1. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
    Oshima K, Takahashi T, Mori T, Matsuyama T, Usuki K, Asano-Mori Y, Nakahara F, Okamoto S, Kurokawa M, Kanda Y.
    Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
    [Abstract] [Full Text] [Related]

  • 2. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M.
    Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
    [Abstract] [Full Text] [Related]

  • 3. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, Chizuka A, Niiya H, Suenaga K, Nakai K, Takeuchi T, Makimoto A, Tanosaki R, Kami M, Tanaka Y, Fujita S, Watanabe T, Kobayashi Y, Tobinai K, Takaue Y.
    Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
    [Abstract] [Full Text] [Related]

  • 4. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
    Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, Kaneda M, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Masauji N, Matsunaga T, Mori A, Mukai M, Nishio M, Noto S, Ota S, Sakai H, Suzuki N, Takahashi T, Tanaka J, Torimoto Y, Yoshida M, Fukuhara T.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
    [Abstract] [Full Text] [Related]

  • 5. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
    Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S.
    Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
    [Abstract] [Full Text] [Related]

  • 6. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Machishima T, Terasako K, Kimura S, Kikuchi M, Nakasone H, Yamazaki R, Kanda J, Kako S, Tanihara A, Nishida J, Kanda Y.
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [Abstract] [Full Text] [Related]

  • 7. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
    Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, Lipton J.
    Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
    [Abstract] [Full Text] [Related]

  • 8. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
    Kim DH, Kumar D, Messner HA, Minden M, Gupta V, Kuruvilla J, Chae YS, Sohn SK, Lipton JH.
    Clin Transplant; 2008 Apr; 22(6):770-9. PubMed ID: 18707605
    [Abstract] [Full Text] [Related]

  • 9. [Analysis of varicella zoster virus infection following allogeneic stem cell transplants].
    Doki N, Hoshino T, Irisawa H, Sakura T, Miyawaki S.
    Rinsho Ketsueki; 2004 Oct; 45(10):1090-4. PubMed ID: 15553042
    [Abstract] [Full Text] [Related]

  • 10. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
    Leung TF, Chik KW, Li CK, Lai H, Shing MM, Chan PK, Lee V, Yuen PM.
    Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
    [Abstract] [Full Text] [Related]

  • 11. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation.
    Suzuki J, Ashizawa M, Okuda S, Wada H, Sakamoto K, Terasako K, Sato M, Kimura SI, Kikuchi M, Nakasone H, Kako S, Yamazaki R, Oshima K, Nishida J, Kanda Y.
    Transpl Infect Dis; 2012 Aug; 14(4):E7-12. PubMed ID: 22340704
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT.
    Klein A, Miller KB, Sprague K, DesJardin JA, Snydman DR.
    Bone Marrow Transplant; 2011 Feb; 46(2):294-9. PubMed ID: 20421867
    [Abstract] [Full Text] [Related]

  • 13. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Machishima T, Terasako K, Kimura SI, Kikuchi M, Nakasone H, Yamazaki R, Kanda J, Kako S, Tanihara A, Nishida J, Kanda Y.
    Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
    [Abstract] [Full Text] [Related]

  • 14. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD).
    Peritz DC, Duncan C, Kurek K, Perez-Atayde AR, Lehmann LE.
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):931-4. PubMed ID: 19131784
    [Abstract] [Full Text] [Related]

  • 15. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA.
    Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
    [Abstract] [Full Text] [Related]

  • 16. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
    Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, Sakai T, Kawanami T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Okazaki T, Nakajima H, Motoo Y, Umehara H.
    Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
    [Abstract] [Full Text] [Related]

  • 17. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
    Umezawa Y, Kakihana K, Oshikawa G, Kobayashi T, Doki N, Sakamaki H, Ohashi K.
    Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
    [Abstract] [Full Text] [Related]

  • 18. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia.
    Sempere A, Sanz GF, Senent L, de la Rubia J, Jarque I, López F, Arilla MJ, Guinot M, Martín G, Martínez J.
    Bone Marrow Transplant; 1992 Dec; 10(6):495-8. PubMed ID: 1362686
    [Abstract] [Full Text] [Related]

  • 19. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
    Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A.
    Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
    [Abstract] [Full Text] [Related]

  • 20. Visceral varicella zoster virus infection after allogeneic stem cell transplantation.
    Doki N, Miyawaki S, Tanaka M, Kudo D, Wake A, Oshima K, Fujita H, Uehara T, Hyo R, Mori T, Takahashi S, Okamoto S, Sakamaki H, Kanto Study Group for Cell Therapy.
    Transpl Infect Dis; 2013 Jun; 15(3):314-8. PubMed ID: 23551634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.